Sunday, February 4, 2007
Continuing: Adult Stem Cell Biotech and Industry
Aastrom Biosciences, Inc. is another stem cell biotech company attracing a lot attention recently. It is located in Ann Arbor, developing Tissue Repair Cell (TRC) products for bone, vascular, cardiac and neural tissue regeneration. Aastrom's Tissue Repair Cells-based products are currently in clinical trials for bone and vascular regeneration applications. Aastrom has reported positive interim clinical trial results from over 230 patients. This company has a few job openings for the biostatistician and scientist.
Again, the above chart shows you the Aastrom stock profile for the last 10 years. Its price has been flucturating widely, not so sweet as Osiris Therapeutics, but it is 10 years trend compared with half year's. Since its current stock price is only about $1 per share, it has been recommended as "low-risk" trials with near future price target of $3.75. Another nice thing I want to mention here is Aastrom offers shareholders Direct Stock Purchase Program (DSPP). The current Aastrom's shareholders don't need to pay brokerage costs and also get a slight discount to recent average market prices at the time of purchase.
Source: CNN money and Aastrom
Subscribe to Posts [Atom]